Chelsea Q Xu1, Yara Mohamad1, Matthew R Kappus2, Brian Boyarsky3, Daniel R Ganger4, Michael L Volk5, Robert S Rahimi6, Andres Duarte-Rojo7, Mara McAdams-DeMarco3,8, Dorry L Segev3,8, Daniela P Ladner9,10, Elizabeth C Verna11, Joshua Grab12, Monica Tincopa13, Michael A Dunn7, Jennifer C Lai1. 1. Department of Medicine, University of California-San Francisco, San Francisco, CA, USA. 2. Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 3. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern Medicine, Chicago, IL, USA. 5. Division of Gastroenterology & Hepatology, and Transplantation Institute, Loma Linda University Health, Loma Linda, CA, USA. 6. Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Baylor Scott and White, Dallas, TX, USA. 7. Center for Liver Diseases, Thomas A. Starzl Transplantation Institute, and Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA. 8. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 9. Division of Transplantation, Department of Surgery, Northwestern Medicine, Chicago, IL, USA. 10. Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 11. Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, NY, USA. 12. Department of Surgery, University of California-San Francisco, San Francisco, CA, USA. 13. Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, MI, USA.
Abstract
BACKGROUND & AIMS: Cirrhosis leads to malnutrition and muscle wasting that manifests as frailty, which may be influenced by cirrhosis aetiology. We aimed to characterize the relationship between frailty and cirrhosis aetiology. METHODS: Included were adults with cirrhosis listed for liver transplantation (LT) at 10 US centrer who underwent ambulatory testing with the Liver Frailty Index (LFI; 'frail' = LFI ≥ 4.4). We used logistic regression to associate aetiologies and frailty, and competing risk regression (LT as the competing risk) to determine associations with waitlist mortality (death/delisting for sickness). RESULTS: Of 1,623 patients, rates of frailty differed by aetiology: 22% in chronic hepatitis C, 31% in alcohol-associated liver disease (ALD), 32% in non-alcoholic fatty liver disease (NAFLD), 21% in autoimmune/cholestatic and 31% in 'other' (P < .001). In univariable logistic regression, ALD (OR 1.53, 95% CI 1.12-2.09), NAFLD (OR 1.64, 95% CI 1.18-2.29) and 'other' (OR 1.58, 95% CI 1.06-2.36) were associated with frailty. In multivariable logistic regression, only ALD (OR 1.40; 95% 1.01-1.94) and 'other' (OR 1.59; 95% 1.05-2.40) remained associated with frailty. A total of 281 (17%) patients died/were delisted for sickness. In multivariable competing risk regression, LFI was associated with waitlist mortality (sHR 1.05, 95% CI 1.03-1.06), but aetiology was not (P > .05 for each). No interaction between frailty and aetiology on the association with waitlist mortality was found (P > .05 for each interaction term). CONCLUSIONS: Frailty is more common in patients with ALD, NAFLD and 'other' aetiologies. However, frailty was associated with waitlist mortality independent of cirrhosis aetiology, supporting the applicability of frailty across all cirrhosis aetiologies.
BACKGROUND & AIMS: Cirrhosis leads to malnutrition and muscle wasting that manifests as frailty, which may be influenced by cirrhosis aetiology. We aimed to characterize the relationship between frailty and cirrhosis aetiology. METHODS: Included were adults with cirrhosis listed for liver transplantation (LT) at 10 US centrer who underwent ambulatory testing with the Liver Frailty Index (LFI; 'frail' = LFI ≥ 4.4). We used logistic regression to associate aetiologies and frailty, and competing risk regression (LT as the competing risk) to determine associations with waitlist mortality (death/delisting for sickness). RESULTS: Of 1,623 patients, rates of frailty differed by aetiology: 22% in chronic hepatitis C, 31% in alcohol-associated liver disease (ALD), 32% in non-alcoholic fatty liver disease (NAFLD), 21% in autoimmune/cholestatic and 31% in 'other' (P < .001). In univariable logistic regression, ALD (OR 1.53, 95% CI 1.12-2.09), NAFLD (OR 1.64, 95% CI 1.18-2.29) and 'other' (OR 1.58, 95% CI 1.06-2.36) were associated with frailty. In multivariable logistic regression, only ALD (OR 1.40; 95% 1.01-1.94) and 'other' (OR 1.59; 95% 1.05-2.40) remained associated with frailty. A total of 281 (17%) patients died/were delisted for sickness. In multivariable competing risk regression, LFI was associated with waitlist mortality (sHR 1.05, 95% CI 1.03-1.06), but aetiology was not (P > .05 for each). No interaction between frailty and aetiology on the association with waitlist mortality was found (P > .05 for each interaction term). CONCLUSIONS: Frailty is more common in patients with ALD, NAFLD and 'other' aetiologies. However, frailty was associated with waitlist mortality independent of cirrhosis aetiology, supporting the applicability of frailty across all cirrhosis aetiologies.
Authors: Natasha H Dolgin; Paulo N A Martins; Babak Movahedi; Kate L Lapane; Fred A Anderson; Adel Bozorgzadeh Journal: Clin Transplant Date: 2016-10-20 Impact factor: 2.863
Authors: Jennifer C Lai; Kenneth E Covinsky; Jennifer L Dodge; W John Boscardin; Dorry L Segev; John P Roberts; Sandy Feng Journal: Hepatology Date: 2017-06-28 Impact factor: 17.425
Authors: Puneeta Tandon; Navdeep Tangri; Lesley Thomas; Laura Zenith; Tahira Shaikh; Michelle Carbonneau; Mang Ma; Robert J Bailey; Saumya Jayakumar; Kelly W Burak; Juan G Abraldes; Amanda Brisebois; Thomas Ferguson; Sumit R Majumdar Journal: Am J Gastroenterol Date: 2016-08-02 Impact factor: 10.864
Authors: Jennifer C Lai; Jennifer L Dodge; Matthew R Kappus; Michael A Dunn; Michael L Volk; Andres Duarte-Rojo; Daniel R Ganger; Robert S Rahimi; Charles E McCulloch; Christine E Haugen; Mara McAdams-DeMarco; Daniela P Ladner; Dorry L Segev; Elizabeth C Verna Journal: J Hepatol Date: 2020-03-30 Impact factor: 25.083
Authors: Rahima A Bhanji; Praveena Narayanan; Michael R Moynagh; Naoki Takahashi; Mounika Angirekula; Cassie C Kennedy; Kristin C Mara; Ross A Dierkhising; Kymberly D Watt Journal: Liver Transpl Date: 2019-01 Impact factor: 5.799
Authors: Jennifer C Lai; Robert S Rahimi; Elizabeth C Verna; Matthew R Kappus; Michael A Dunn; Mara McAdams-DeMarco; Christine E Haugen; Michael L Volk; Andres Duarte-Rojo; Daniel R Ganger; Jacqueline G O'Leary; Jennifer L Dodge; Daniela Ladner; Dorry L Segev Journal: Gastroenterology Date: 2019-01-19 Impact factor: 22.682
Authors: Ani Kardashian; Jin Ge; Charles E McCulloch; Matthew R Kappus; Michael A Dunn; Andres Duarte-Rojo; Michael L Volk; Robert S Rahimi; Elizabeth C Verna; Daniel R Ganger; Daniela Ladner; Jennifer L Dodge; Brian Boyarsky; Mara McAdams-DeMarco; Dorry L Segev; Jennifer C Lai Journal: Hepatology Date: 2020-10-30 Impact factor: 17.425